KDOAM-25 citrate 是有效，高选择性的组蛋白赖氨酸脱甲基酶 5 (KDM5) 抑制剂，对 KDM5A，KDM5B，KDM5C，KDM5D 的 IC₅₀ 分别为 71 nM，19 nM，69 nM，69 nM。KDOAM-25 citrate 可增加转录起始位点的整体 H3K4 甲基化，并损害多发性骨髓瘤 MM1S 细胞的增殖。

KDOAM-25 citrate is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC 50 s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 citrate increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells.

Solid

KDM5

KDOAM-25 citrate inhibits most potently KDM5B with an IC50 of ～50 μM and the other KDM5 family members at concentrations above 100 μM. KDOAM-25 citrate shows no cellular activity on any of the other tested JmjC family members.
KDOAM-25 citrate is able to reduce the viability of MM1S cells with an IC50 of ～30 μM after a delay of 5-7 days.
KDOAM-25 citrate treatment results in a G1 cell-cycle arrest with an increased proportion of MM1S in G1 and a decrease of the proportion of cells in G2 without an increase in the proportion of cells in the apoptotic sub-G1 phase.
KDOAM-25 citrate (50 μM) increases with approximately twice as much H3K4me3 in in multiple myeloma cells.
has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

4°C, stored under nitrogen In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

[1]. Tumber A, et al. Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells. Cell Chem Biol. 2017 Mar 16;24(3):371-380.

In Vitro: DMSO : 200 mg/mL (400.39 mM; Need ultrasonic)H₂O : 100 mg/mL (200.20 mM; Need ultrasonic)配制储备液